Literature DB >> 25742451

Training on trials: patients taught the language of drug development.

Shraddha Chakradhar1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25742451     DOI： 10.1038/nm0315-209

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

Review 1.  Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.

Authors:  Hojjat Soofi; Evert van Leeuwen
Journal:  J Community Genet       Date:  2016-08-05

Review 2.  Practices of patient engagement in drug development: a systematic scoping review.

Authors:  Olga Zvonareva; Constanța Craveț; Dawn P Richards
Journal:  Res Involv Engagem       Date:  2022-06-29

Review 3.  Patient involvement in clinical research: why, when, and how.

Authors:  José A Sacristán; Alfonso Aguarón; Cristina Avendaño-Solá; Pilar Garrido; Juan Carrión; Alipio Gutiérrez; Robert Kroes; Angeles Flores
Journal:  Patient Prefer Adherence       Date:  2016-04-27       Impact factor: 2.711

4.  Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Authors:  Dianne Nicol; Lisa Eckstein; Michael Morrison; Jacob S Sherkow; Margaret Otlowski; Tess Whitton; Tania Bubela; Kathryn P Burdon; Don Chalmers; Sarah Chan; Jac Charlesworth; Christine Critchley; Merlin Crossley; Sheryl de Lacey; Joanne L Dickinson; Alex W Hewitt; Joanne Kamens; Kazuto Kato; Erika Kleiderman; Satoshi Kodama; John Liddicoat; David A Mackey; Ainsley J Newson; Jane Nielsen; Jennifer K Wagner; Rebekah E McWhirter
Journal:  Genome Med       Date:  2017-09-25       Impact factor: 11.117

5.  Health democracy in Europe: Cancer patient organization participation in health policy.

Authors:  Kyriakos Souliotis; Lily E Peppou; Eirini Agapidaki; Chara Tzavara; Dominique Debiais; Stanimir Hasurdjiev; Francois Sarkozy
Journal:  Health Expect       Date:  2017-11-01       Impact factor: 3.377

6.  An integrated conceptual framework for evaluating and improving 'understanding' in informed consent.

Authors:  Sabine Bossert; Daniel Strech
Journal:  Trials       Date:  2017-10-17       Impact factor: 2.279

7.  The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.

Authors:  Noel T Southall; Madhusudan Natarajan; Lilian Pek Lian Lau; Anneliene Hechtelt Jonker; Benoît Deprez; Tim Guilliams; Lawrence Hunter; Carin Ma Rademaker; Virginie Hivert; Diego Ardigò
Journal:  Orphanet J Rare Dis       Date:  2019-10-15       Impact factor: 4.123

8.  Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.

Authors:  T Morel; S Aymé; D Cassiman; S Simoens; M Morgan; M Vandebroek
Journal:  Orphanet J Rare Dis       Date:  2016-05-26       Impact factor: 4.123

9.  An Analysis of Sponsors/Collaborators of 69,160 Drug Trials Registered with ClinicalTrials.gov.

Authors:  Shruthi Muralidharan Keezhupalat; Ankeet Naik; Saurabh Gupta; Raghunathan Srivatsan; Gayatri Saberwal
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

10.  Patient Engagement Partnerships in Clinical Trials: Development of Patient Partner and Investigator Decision Aids.

Authors:  Monica Parry; Ann Kristin Bjørnnes; Karine Toupin-April; Adhiyat Najam; David Wells; Aditi Sivakumar; Dawn P Richards; Tina Ceroni; Marianne Park; Anne K Ellis; Ian Gilron; Susan Marlin
Journal:  Patient       Date:  2020-10-07       Impact factor: 3.883
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.